Ovid Therapeutics Sees Opportunity with Phase 2 Ready Assets and PIPE Funding

Ovid Therapeutics, a biotech company, has experienced a setback with its lead drug, soticlestat, failing a Phase 3 trial. Despite this, the company's stock has not yet recovered. However, Ovid's GABA-AT inhibitor, OV329, remains a promising asset and the company has received PIPE funding. This could be an opportunity for Ovid to seize the moment and move forward with OV329 in Phase 2 trials.